Amicus Therapeutics, Inc. (FOLD)
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Investigation
08/27/2021
Initial Lawsuit
08/27/2021
Lawsuit Progression
05/26/2022
Did Katapult mislead investors in connection with its going public merger with FinServ Acquisition and its eCommerce sales & consumer spending?
This post is open for investors to gather facts, and findings and track their exposure to related lawsuits. We invite investors and shareholders to contribute to this investigation for their own benefit, add events to the factual timeline below and vote on events’ pertinence.
A lawsuit was subsequently filed. We will update this post as it unfolds.
08/10/2021
Katapult announces its Q2 2021 financials results, including a net loss of $8.1 million down from $5.1 million of net income in Q2 2020. Adjusted net income comes at $1.5 million, down 70.4% from $5.2 million in the second quarter of 2020.
“Since our Q1 earnings call and continuing to date, many new developments emerged that have an impact to our business. We observed meaningful changes in both e-commerce retail sales forecasts and consumer spending behavior, and in the past few weeks, the onset of new policies from the COVID-19 variants. Given the current macro trends and uncertainty to accurately predict our consumer’s buying behaviors for the remainder of the year, we believe it is best to remove explicit guidance for the remainder of 2021. While the short-term outlook may not be 100% clear, we do continue to believe in our mission, our core business fundamentals, and are extremely pleased with the progress of our strategic investments that will drive long term growth.”
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$4.26 | $9.73 | $-5.47 | -56.22% |
A Katapult investor filed a securities class action lawsuit on behalf of persons and entities that purchased or otherwise acquired Katapult Holdings, Inc. securities between December 18, 2020, and August 10, 2021, inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors:
(1) that Katapult was experiencing declining e-commerce retail sales and consumer spending,
(2) that despite Katapult’s assertions that it was clear and compelling value proposition to both consumers and merchants, transforming the way nonprime consumers shop for essential good sand enabling merchant access to this underserved segment, Katapult lacked visibility into its consumers’ future buying behavior; and
(3) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.
05/26/2022
The court issued an order appointing the lead plaintiff and lead counsel.
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Kewaunee Scientific Corporation (KEQU) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.